Combination therapy for HER2-positive advanced bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combo—disitamab vedotin, lenvatinib, and an immunotherapy—for people with advanced bile duct cancer that has HER2 protein. It aims to see if this combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bile duct cancer (including gallbladder cancer) that cannot be removed by surgery or has spread.
- Your cancer tests positive for HER2 (a protein that helps cells grow).
- You have not had previous treatment targeting HER2.
- You are in fairly good health (able to care for yourself and out of bed for at least half the day).
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
This trial tests a new combination of two drugs (T-DXd and rilvegostomig) for people with advanced bile duct cancer that has not been treated before. The cancer must have high levels of a protein called HER2. This study compares the new drugs to standard treatments.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) as a first treatment for people with advanced HER2-positive or HER2-low bile duct or gallbladder cancer. The goal is to see if this combination helps shrink or control the cancer.
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.